Gaucher disease: Pediatric concerns

Pediatric Drugs

Volumn 4, Issue 7, 2002, Pages 417-426

  Elstein, Deborah ^a   Abrahamov, Aya ^a   Dweck, Altoon ^a   Hadas Halpern, Irith ^a   Zimran, Ari ^a  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALGLUCERASE; BIOCHEMICAL MARKER; ENZYME INHIBITOR; GLUCOSYLCERAMIDASE; IMIGLUCERASE; MIGLUSTAT; N BUTYL DEOXYNOJIRMYCIN; UNCLASSIFIED DRUG;

ANEMIA; AUTOSOMAL RECESSIVE DISORDER; BONE DISEASE; BONE MARROW TRANSPLANTATION; CATCH UP GROWTH; CHILD; CLINICAL FEATURE; COST BENEFIT ANALYSIS; DISEASE CLASSIFICATION; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME REPLACEMENT; FOLLOW UP; GAUCHER DISEASE; GENE MUTATION; GENE THERAPY; HETEROZYGOTE; HUMAN; INCIDENCE; LABORATORY DIAGNOSIS; LUNG DISEASE; MASS SCREENING; ORTHOPEDIC SURGERY; PRENATAL DIAGNOSIS; PREVALENCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SPLENECTOMY; THROMBOCYTOPENIA; PATHOPHYSIOLOGY; PEDIATRICS; PRESCHOOL CHILD;

CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; GAUCHER DISEASE; HUMANS; PEDIATRICS;

EID: 0035985744     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128072-200204070-00001     Document Type: Review

References (41)

1. Glucosylceramide lipidoses
2. Gaucher's disease: Molecular, genetic and enzymological aspects
3. Gaucher disease mutations in non-Jewish patients
4. Asymptomatic Gaucher disease implications for large-scale screening
5. Gaucher's disease
6. Glucosylsphingosine accumulation in mice and patients with type 2 Gaucher disease begins early in gestation
7. Gaucher disease: Norbottnian type
8. Clinical and genetic studies of Japanese homozygotes for the Gaucher disease L444P mutation
9. Bone scans in the diagnosis of bone crisis in patients who have Gaucher disease
10. Skeletal involvement in Gaucher disease
11. Bone density in type I Gaucher disease
12. The nature and extent of jaw involvement in Gaucher disease: Observations in a series of 28 patients
13. Pulmonary function abnormalities in type I Gaucher disease
14. The role of neurogenetics in Gaucher disease
15. Lung involvement and enzyme replacement therapy in Gaucher's disease
16. Gaucher disease: Current issues in diagnosis and treatment
17. Marked elevation of plasma chitotriosidase activity: A novel hallmark of Gaucher disease
18. Plasma chitotriosidase activity in patients with Gaucher disease who have been treated either by bone marrow transplantation or by enzyme replacement therapy
19. Splenectomy in Gaucher disease: New management dilemmas
20. Outcome of partial splenectomy in type I Gaucher disease
21. Outcome of total hip arthroplasty in patients with Gaucher disease
22. Efficient transfer and sustained high expression of the human glucocerebrosidase gene in mice and their functional macrophages following transplantation of bone marrow transduced by a retroviral vector
23. Ten years' experience of bone marrow transplantation for Gaucher disease
24. Enzyme therapy for Gaucher disease: The first 5 years
25. Enzyme replacement therapy for Gaucher disease: Skeletal responses to macrophage-targeted glucocerebrosidase
26. Effect of low-dose enzyme replacement therapy on bones in Gaucher patients with severe skeletal involvement
27. Low-dose high-frequency enzyme replacement therapy prevents fractures without complete suppression of painful bone crises in patients with severe juvenile onset type I Gaucher disease
28. Treatment of type I Gaucher's disease affecting bone with aminohydroxypropylidene bisphosphonate (pamidronate)
29. Alendronate disodium improves bone mineral density in adults receiving enzyme replacement therapy (ERT) for Gaucher disease
30. Increased basal glucose production in type I Gaucher disease
31. Reply to vom Dabl et al. Clinical monitoring after cessation of enzyme replacement therapy in M. Gaucher
32. Echocardiographic assessment of pulmonary hypertension in Gaucher disease
33. Withdrawal of enzyme replacement therapy in Gaucher disease
34. The clinical course of treated and untreated Gaucher disease: A study of 45 patients
35. A practical approach to diagnosis and management of Gaucher's disease
36. Ethical considerations for enzyme replacement therapy in neuronopathic Gaucher disease
37. The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher's disease
38. Management or neuronopathic Gaucher disease: A European consensus
39. Children with type I Gaucher disease: Growing into adulthood with and without enzyme therapy
40. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis
41. The molecular biology of Gaucher disease and the potential for gene therapy